CC BY 4.0 · TH Open 2022; 06(04): e408-e420
DOI: 10.1055/a-1937-9692
Original Article

Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records

1   Northwell Health at Lenox Hill Hospital, New York, New York, United States
2   The Institute of Health Systems Science at the Feinstein Institutes for Medical Research, Manhasset, New York, United States
3   The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States
,
James M. Crawford
2   The Institute of Health Systems Science at the Feinstein Institutes for Medical Research, Manhasset, New York, United States
3   The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States
,
Yen-Wen Cindy Chen
4   Janssen Scientific Affairs, LLC, Titusville, New Jersey, United States
,
Veronica Ashton
4   Janssen Scientific Affairs, LLC, Titusville, New Jersey, United States
,
Alicia K. Campbell
4   Janssen Scientific Affairs, LLC, Titusville, New Jersey, United States
,
Dejan Milentijevic
4   Janssen Scientific Affairs, LLC, Titusville, New Jersey, United States
,
W. Frank Peacock
5   Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas, United States
› Author Affiliations
Funding This work was supported by Janssen Scientific Affairs, LLC, United States.


Abstract

Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some patients experience cardiovascular complications, including thromboembolic events and death. Data are needed to better inform prevention and treatment of these events. This analysis was designed to describe patient characteristics, medication use, thromboembolic events, and all-cause mortality in hospitalized COVID-19 patients in the United States.

Methods This retrospective, observational cohort study identified adults hospitalized with COVID-19 (January 21, 2020–January 07, 2021) in the deidentified Optum COVID-19 Electronic Health Records dataset. Thromboembolic events and all-cause mortality were collected at any time during the variable follow-up period (up to 50 weeks).

Results Of 181,995 COVID-19 patients who met eligibility criteria, 40,524 (22.3%) were hospitalized with COVID-19. Hospitalized patients had a mean age of 63 years and a Quan–Charlson comorbidity index of 1.3. Anticoagulants were used in 89.2% of patients during hospitalization and in 18.7% of postdischarge patients. Of hospitalized patients, 17.6% had a thromboembolic event during the entire follow-up period (mean time to the first event of 15 days), of whom 13.4% had an event during hospitalization; of discharged patients, 4.3% had a thromboembolic event (mean time from discharge to event of 43 days). Death during the follow-up period was reported in 15.0% of patients.

Conclusions In this large, observational cohort study, patients hospitalized with COVID-19 had high rates of thromboembolic events during hospitalization and in the postdischarge period; mortality was also high in this population. Anticoagulant use was common during hospitalization. These findings support further studies to optimize in-hospital and extended prophylaxis for hospitalized COVID-19 patients.

Data Availability

Data for these analyses were made available to the authors through third-party license from Optum, a commercial data provider. As such, the authors cannot make these data publicly available due to data use agreement. Other researchers can access these data by purchasing a license through Optum. Inclusion criteria specified in the Methods section would allow other researchers to identify the same cohort of patients we used for these analyses. Interested individuals may see https://www.optum.com/business/solutions/life-sciences/explore-data.html for more information on accessing Optum data.


Author Contributions

W.F.P., J.M.C., and A.C.S. contributed to the analysis and/or interpretation of data; critical writing or revising the intellectual content; and final approval of the version to be published. Y.-W.C., V.A., A.K.C., and D.M. contributed to the concept and design, analysis, and/or interpretation of data; critical writing or revising the intellectual content; and final approval of the version to be published.


Supplementary Material



Publication History

Received: 22 July 2022

Accepted: 30 August 2022

Accepted Manuscript online:
07 September 2022

Article published online:
18 November 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020; 38 (07) 1504-1507
  • 2 Tan BK, Mainbourg S, Friggeri A. et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax 2021; 76 (10) 970-979
  • 3 Burn E, Duarte-Salles T, Fernandez-Bertolin S. et al. Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study. Lancet Infect Dis 2022; 22 (08) 1142-1152
  • 4 Snell J. SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: a review. Am J Emerg Med 2021; 40: 188-192
  • 5 Cohen SL, Gianos E, Barish MA. et al; Northwell Health COVID-19 Research Consortium. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost 2021; 121 (08) 1043-1053
  • 6 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
  • 7 Glober N, Stewart L, Seo J. et al. Incidence and characteristics of arterial thromboemboli in patients with COVID-19. Thromb J 2021; 19 (01) 104
  • 8 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020; 120 (12) 1642-1653
  • 9 Ranucci M, Ballotta A, Di Dedda U. et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; 18 (07) 1747-1751
  • 10 Romiti GF, Corica B, Lip GYH, Proietti M. Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: a systematic review and meta-analysis. J Clin Med 2021; 10 (11) 2490
  • 11 Avula A, Nalleballe K, Toom S. et al. Incidence of thrombotic events and outcomes in COVID-19 patients admitted to intensive care units. Cureus 2020; 12 (10) e11079
  • 12 Mendes A, Herrmann FR, Genton L. et al. Incidence, characteristics and clinical relevance of acute stroke in old patients hospitalized with COVID-19. BMC Geriatr 2021; 21 (01) 52
  • 13 Hendren NS, de Lemos JA, Ayers C. et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation 2021; 143 (02) 135-144
  • 14 Alonso-Fernández A, Toledo-Pons N, Cosío BG. et al. Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: a prospective study. PLoS One 2020; 15 (08) e0238216
  • 15 Moll M, Zon RL, Sylvester KW. et al. VTE in ICU patients with COVID-19. Chest 2020; 158 (05) 2130-2135
  • 16 Zhang R, Ni L, Di X. et al. Systematic review and meta-analysis of the prevalence of venous thromboembolic events in novel coronavirus disease-2019 patients. J Vasc Surg Venous Lymphat Disord 2021; 9 (02) 289-298.e5
  • 17 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021; 5 (03) 872-888
  • 18 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv 2021; 5 (20) 3951-3959
  • 19 Moores LK, Tritschler T, Brosnahan S. et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest 2020; 158 (03) 1143-1163
  • 20 National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed September 21, 2021, at: https://www.covid19treatmentguidelines.nih.gov/
  • 21 Spyropoulos AC, Levy JH, Ageno W. et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1859-1865
  • 22 Lynn L, Reyes JA, Hawkins K. et al. The effect of anticoagulation on clinical outcomes in novel coronavirus (COVID-19) pneumonia in a U.S. cohort. Thromb Res 2021; 197: 65-68
  • 23 Sadeghipour P, Talasaz AH, Rashidi F. et al; INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA 2021; 325 (16) 1620-1630
  • 24 Gerotziafas GT, Catalano M, Colgan MP. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
  • 25 Sholzberg M, Tang GH, Rahhal H. et al; RAPID trial investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375 (2400): n2400
  • 26 Spyropoulos AC, Goldin M, Giannis D. et al; HEP-COVID Investigators. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181 (12) 1612-1620
  • 27 Goligher EC, Bradbury CA, McVerry BJ. et al; REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 2021; 385 (09) 777-789
  • 28 Lawler PR, Goligher EC, Berger JS. et al; ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med 2021; 385 (09) 790-802
  • 29 Quan H, Li B, Couris CM. et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173 (06) 676-682
  • 30 Levy TJ, Richardson S, Coppa K. et al. Development and validation of a survival calculator for hospitalized patients with COVID-19. medRxiv 2020; (e-pub ahead of print) DOI: 10.1101/2020.04.22.20075416.
  • 31 Goldin M, Lin SK, Kohn N. et al. External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. J Thromb Thrombolysis 2021; 52 (04) 1032-1035
  • 32 Spyropoulos AC, Cohen SL, Gianos E. et al; COVID-19 Consortium Group. Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Res Pract Thromb Haemost 2021; 5 (02) 296-300
  • 33 Vaughn VM, Yost M, Abshire C. et al. Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19. JAMA Netw Open 2021; 4 (06) e2111788
  • 34 Giannis D, Allen SL, Tsang J. et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood 2021; 137 (20) 2838-2847
  • 35 Roberts LN, Whyte MB, Georgiou L. et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 2020; 136 (11) 1347-1350
  • 36 Patell R, Bogue T, Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood 2020; 136 (11) 1342-1346
  • 37 Rashidi F, Barco S, Kamangar F. et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res 2021; 198: 135-138
  • 38 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
  • 39 Berkman SA. Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients. Postgrad Med 2021; 133 (Suppl. 01) 51-63
  • 40 Spyropoulos AC, Ageno W, Albers GW. et al. Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. J Am Coll Cardiol 2020; 75 (25) 3140-3147
  • 41 Gibson CM, Korjian S, Chi G. et al; APEX Investigators. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy. J Am Heart Assoc 2017; 6 (07) e006015
  • 42 Ramacciotti E, Barile Agati L, Calderaro D. et al; MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399 (10319): 50-59
  • 43 Wang PG, Brisbon NM, Hubbell H. et al. Is the gap closing? Comparison of sociodemographic disparities in COVID-19 hospitalizations and outcomes between two temporal waves of admissions. J Racial Ethn Health Disparities 2022; 1-10 (e-pub ahead of print) DOI: 10.1007/s40615-022-01249-y.
  • 44 Radovanovic D, Pini S, Franceschi E. et al. Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: an observational prospective study. Respir Med 2021; 178: 106323
  • 45 Wichmann D, Sperhake JP, Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020; 173 (04) 268-277
  • 46 Centers for Disease Control and Prevention. ICD-10-CM official coding guidelines - supplement. Coding encounters related to COVID-19 coronavirus outbreak. Effective: February 20, 2020. Accessed June 21, 2022, at: https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf
  • 47 Centers for Disease Control and Prevention. ICD-10-CM official coding and reporting guidelines. April 1, 2020 through September 30, 2020. Accessed June 21, 2022, at: https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf
  • 48 Fernandez AR, Crowe RP, Bourn S. et al. COVID-19 preliminary case series: characteristics of EMS encounters with linked hospital diagnoses. Prehosp Emerg Care 2021; 25 (01) 16-27
  • 49 Howard A. COVID-19 and sepsis coding: new guidelines. Accessed June 21, 2022, at: https://insideangle.3m.com/his/blog-post/covid-19-and-sepsis-coding-new-guidelines/
  • 50 Quan H, Sundararajan V, Halfon P. et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43 (11) 1130-1139